THE DEVELOPMENT OF POST-INFLAMMATORY GASTROINTESTINAL SYMPTOMS IN PATIENTS WHO HAVE HAD AN IMMUNE CHECKPOINT INHIBITOR-RELATED ADVERSE EVENT IN THE GASTROINTESTINAL TRACT

被引：0
|
作者：
Varma, Sanskriti
Staller, Kyle
Dougan, Michael
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1356
引用
收藏
页码：S1038 / S1038
页数：1
相关论文
共 50 条
  • [41] Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
    Ladouceur, Alexandra
    Mouterde, Gael
    Tison, Alice
    Bitoun, Samuel
    Mary-Prey, Sorilla
    Dutriaux, Caroline
    Gerard, Emilie
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Zysman, Maeva
    Veillon, Remi
    Domblides, Charlotte
    Daste, Amaury
    Gross-Goupil, Marine
    Sionneau, Baptiste
    Lefort, Felix
    Larroquette, Mathieu
    Barnetche, Thomas
    Richez, Christophe
    Truchetet, Marie-Elise
    Schaeverbebke, Thierry
    Kostine, Marie
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2080 - 2082
  • [42] Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
    Ladouceur, Alexandra
    Barnetche, Thomas
    Mouterde, Gael
    Tison, Alice
    Bitoun, Samuel
    Prey, Sorilla
    Dutriaux, Caroline
    Gerard, Emilie
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Zysman, Maeva
    Veillon, Remi
    Domblides, Charlotte
    Daste, Amaury
    Gross-Goupil, Marine
    Sionneau, Baptiste
    Lefort, Felix
    Larroquette, Mathieu
    Richez, Christophe
    Truchetet, Marie-Elise
    Schaeverbeke, Thierry
    Kostine, Marie
    RMD OPEN, 2023, 9 (04):
  • [43] Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report
    Arakaki, Shintaro
    Ono, Shinichiro
    Kawamata, Futoshi
    Ishino, Shinichiro
    Uesato, Yasunori
    Nakajima, Tomo
    Nishi, Yukiko
    Morishima, Satoko
    Arakaki, Shingo
    Maeshiro, Tatsuji
    Souri, Masayoshi
    Ichinose, Akitada
    Masuzaki, Hiroaki
    Takatsuki, Mitsuhisa
    SURGICAL CASE REPORTS, 2023, 9 (01)
  • [44] Fatal acquired coagulation factor V deficiency after hepatectomy for advanced hepatocellular carcinoma as a possible immune checkpoint inhibitor-related adverse event: a case report
    Shintaro Arakaki
    Shinichiro Ono
    Futoshi Kawamata
    Shinichiro Ishino
    Yasunori Uesato
    Tomo Nakajima
    Yukiko Nishi
    Satoko Morishima
    Shingo Arakaki
    Tatsuji Maeshiro
    Masayoshi Souri
    Akitada Ichinose
    Hiroaki Masuzaki
    Mitsuhisa Takatsuki
    Surgical Case Reports, 9
  • [45] Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
    Ghosh, Nilasha
    Chan, Karmela Kim
    Jivanelli, Bridget
    Bass, Anne
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [46] Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
    Yang, Wenhan
    Men, Peng
    Xue, Huimin
    Jiang, Mingyan
    Luo, Qiuhua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [47] Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
    Jokimaki, Anna
    Hietala, Henna
    Lemma, Jasmiini
    Karhapaa, Hanna
    Rintala, Anna
    Kaikkonen, Jari-Pekka
    Sunela, Kaisa
    Boman, Eva
    Jukkola, Arja
    Tiainen, Satu
    Seppala, Jan
    Ronka, Aino
    Hakkarainen, Heikki
    Karna, Aarno
    Iivanainen, Sanna
    Koivunen, Jussi
    Auvinen, Paivi
    Hernberg, Micaela
    Kuusisto, Milla
    Selander, Tuomas
    Kuittinen, Outi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (10) : 3337 - 3347
  • [48] Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events
    Anna Jokimäki
    Henna Hietala
    Jasmiini Lemma
    Hanna Karhapää
    Anna Rintala
    Jari-Pekka Kaikkonen
    Kaisa Sunela
    Eva Boman
    Arja Jukkola
    Satu Tiainen
    Jan Seppälä
    Aino Rönkä
    Heikki Hakkarainen
    Aarno Kärnä
    Sanna Iivanainen
    Jussi Koivunen
    Päivi Auvinen
    Micaela Hernberg
    Milla Kuusisto
    Tuomas Selander
    Outi Kuittinen
    Cancer Immunology, Immunotherapy, 2023, 72 : 3337 - 3347
  • [49] Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients
    Kawata, Satoshi
    Kozawa, Junji
    Yoneda, Sho
    Fujita, Yukari
    Kashiwagi-Takayama, Risa
    Kimura, Takekazu
    Hosokawa, Yoshiya
    Baden, Megu Y.
    Uno, Sae
    Uenaka, Rikako
    Namai, Kazuyuki
    Koh, Yoko
    Tomimaru, Yoshito
    Hirata, Haruhiko
    Uemura, Motohide
    Nojima, Satoshi
    Morii, Eiichi
    Eguchi, Hidetoshi
    Imagawa, Akihisa
    Shimomura, Iichiro
    DIABETES, 2023, 72 (04) : 511 - 519
  • [50] Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
    Sun, Qian
    Sun, Hongyan
    Wu, Nan
    Hu, Yue
    Zhang, Fangqing
    Cong, Xianling
    FRONTIERS IN ONCOLOGY, 2022, 12
12345